The Next Decade of Immune Checkpoint TherapyPadmanee Sharma, James P. Allison|Cancer Discovery|2021Cited by 739
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, James P. Allison et al.|Cancer Discovery|2018Cited by 570
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinomaPadmanee Sharma, Eiichi Sato, Yu Shen et al.|Proceedings of the National Academy of Sciences|2007Cited by 517
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemiaPatrick Williams, Naval Daver, Sreyashi Basu et al.|Cancer|2018Cited by 339
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|Cancer Cell|2022Cited by 338